Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/22/2021 | Series E | $80.48MM | $xx.xx | $28.3B | Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
102,671,041
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital
|
||||||
07/09/2020 | Series D-2 | $17MM | $xx.xx | $15.73B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,598,481
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
04/02/2019 | Series D-1 | $40MM | $xx.xx | $13.95B | Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
57,878,742
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital
|
||||||
12/21/2017 | Series C-2 | $12.12MM | $xx.xx | $7.31B | Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
33,218,192
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
|
||||||
12/21/2017 | Series C-1 | $30.29MM | $xx.xx | $7.31B | Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
58,109,711
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
|
||||||
03/05/2015 | Series B | $28.21MM | $xx.xx | $5.03B | Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
22,705,646
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital
|
||||||
08/17/2014 | Series A-2 | $5.37MM | $xx.xx | $2.21B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,325,021
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
07/04/2013 | Series A-1 | $8.2MM | $xx.xx | $2.91B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,298,732
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
08/26/2011 | Series A | $3.4MM | $xx.xx | $1.6B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,701,141
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|